By Colin Kellaher

Abbott Laboratories (ABT) on Tuesday said the U.S. Food and Drug Administration approved a new surgical technique for the company's HeartMate 3 heart pump that can help patients avoid open-heart surgery.

The Abbott Park, Ill., maker of healthcare products said the HeartMate 3 can now be implanted through an incision in the chest wall.

Abbott said the new technique can result in less bleeding and a shorter recovery time for patients compared with open-heart surgery.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

January 07, 2020 10:32 ET (15:32 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Abbott Laboratories Charts.
Abbott Laboratories (NYSE:ABT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Abbott Laboratories Charts.